Will the Universal Health Insurance Authority (UHIA), MetLife Egypt, AXA Egypt, and Bupa Egypt cover this?

Each insurer assesses named-patient imports case by case. Some reimburse fully when Camzyos is on their formulary even if not currently stocked, some reimburse a percentage subject to copay, and many require pre-authorisation. We supply the documentation set that allows your insurer to assess the case; the claim itself sits with you or your hospital.

Is the FDA-approved indication recognised by EDA?

The EDA named-patient pathway exists precisely to permit access when the local registration or stocking lags the FDA label. The application documents the FDA indication, the reference-authority approval, and the local gap; EDA review focuses on the clinical justification rather than re-litigating the FDA decision.

My physician is licensed in one emirate / state / province and the hospital is in another. Is that fine?

Any Egyptian-licensed physician practicing in good standing in the jurisdiction of the dispensing facility has signing authority on the clinical justification letter. The Egyptian Medical Syndicate and the EDA verifies the active license; the EDA application records both the prescribing physician and the dispensing facility.

Can I receive Camzyos at home?

The dispensing facility must be Egyptian-licensed. The hospital outpatient or specialty pharmacy releases the medicine to you after final verification, and you then administer or self-administer at home where the FDA label permits, after the dispensing pharmacy's training. The cold-chain or controlled-storage handoff ends at the dispensing pharmacy; home storage and any handling protocol are part of your patient onboarding kit.

What about competitors or alternative therapies in the same class?

Choice of therapy depends on the patient's full phenotype, prior therapy, and the prescriber's judgment. Reserve Meds coordinates whichever medicine the physician has prescribed; we do not substitute, advise on substitution, or promote one brand over another.

Indicative drug-only band: USD 5,000 to 7,000 per month. Delivered quote within 24h.Get my quote

Camzyos access in Egypt: the EDA named-patient pathway

How patients in the Arab Republic of Egypt legally obtain Camzyos (mavacamten) when the locally registered indication, stocked presentation, or payer coverage does not match what the prescribing physician has written.

Last reviewed 2026-05-12 by Reserve Meds clinical and regulatory team.

Quick orientation

Patients in Egypt access Camzyos (mavacamten) for symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in NYHA class II to III adults under the FDA REMS-restricted label through the EDA named-patient pathway, an Egyptian Drug Authority-administered mechanism that allows an Egyptian-licensed physician at a registered facility to import the FDA-labelled product for a specific named patient. This page details the documentation, approval timeline, and real cost in EGP.

Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.

Reserved for you.

How Camzyos reaches patients in Egypt

Camzyos (mavacamten, the first-in-class cardiac myosin inhibitor FDA-approved April 2022 for symptomatic obstructive hypertrophic cardiomyopathy in NYHA class II to III adults) is not visible on the EDA registered-drug database at eservices.edaegypt.gov.eg/EDASearch/SearchRegDrugs as of 2026-05-31. Egyptian patients access Camzyos through Personal Importation of Unregistered Medicines, the EDA Central Administration for Pharmaceutical Affairs permit administered under Pharmacy Practice Law No. 127 of 1955 read with Health Minister Decree No. 296 of 2009 (importation of unregistered drugs for individual cases) and EDA implementing circulars. Egypt's broader pharmaceutical-law framework was updated by Law No. 151 of 2019 establishing the EDA. The Camzyos-specific clinical justification must demonstrate confirmed obstructive HCM diagnosis (peak left ventricular outflow tract gradient at least 50 mmHg by echocardiography), NYHA class II to III symptoms, baseline LVEF at least 55%, and CYP2C19 metaboliser-status starting-dose selection per the FDA label. The supporting medical report must be stamped by the treating Egyptian-licensed cardiologist and submitted to the EDA in person at the headquarters in Cairo or via the regional EDA office. The application package includes: stamped medical report with diagnosis and medical justification, prescription (drug INN, strength, dosage form, quantity for 3-month supply), patient national ID, and pro-forma invoice from the foreign supplier. The EDA does not publish a fixed processing-time SLA; turnaround is typically 1 to 3 weeks when documentation is complete. The permit is single-consignment.

Where Camzyos is dispensed in Egypt

Camzyos is an oral self-administered chronic cardiology therapy with serial echocardiographic surveillance; the dispensing setting is an HCM-experienced cardiology service rather than an oncology unit. Egyptian tertiary cardiology nodes equipped for the diagnostic workup and the FDA-label echocardiographic surveillance schedule (weeks 4, 8, 12, 24, then every 12 weeks) include the Cairo University Hospitals (Kasr Al-Ainy) Department of Cardiology in Cairo, a primary referral centre for inherited cardiomyopathy; the National Heart Institute (Imbaba) in Giza, MOH's flagship cardiothoracic referral facility; Ain Shams University Hospitals Department of Cardiology in Cairo; Alexandria University Hospitals Department of Cardiology (Shatby and Smouha campuses); the Magdi Yacoub Heart Foundation Aswan Heart Centre at magdiyacoubfoundation.org, which runs structured cardiomyopathy and inherited-cardiovascular-disease services and publishes consultant rosters; and Mansoura University Hospitals Cardiology service. The Magdi Yacoub Foundation Aswan Heart Centre and Cairo University Kasr Al-Ainy are the most frequent points of contact for HCM diagnostic confirmation by echocardiography plus cardiac MRI plus genetic testing where indicated. CYP2C19 phenotyping is available in selected Cairo university and private-tertiary genetics labs.

What Camzyos costs in Egypt

The US reference WAC for Camzyos is approximately USD 7,800 to USD 8,500 per 30-day supply across 2.5 mg, 5 mg, 10 mg, and 15 mg strengths per Drugs@FDA at accessdata.fda.gov/scripts/cder/daf. Annual WAC at labelled dose runs USD 90,000 to USD 100,000. No public local-currency EGP benchmark for Camzyos is observed on the EDA registered-drug database or via the Unified Procurement, Medical Supply and Healthcare Technology Management Authority (UPA) at upa.gov.eg as of 2026-05-31; the drug is not currently EDA-registered. Do not estimate. Price snapshot: 2026-05-31. The Egyptian Pound has been volatile (multiple devaluations 2022 to 2024); the EGP-to-USD spot rate from the Central Bank of Egypt on the date of any final quote should be footnoted. Cost layers: ambient-temperature international logistics into Egypt (low to mid four-figure USD; Camzyos is a stable oral capsule), EDA permit and Egyptian customs (nominal relative to drug cost), the dispensing hospital's cardiology and surveillance-echocardiography fees (5 echocardiograms in year one per the FDA REMS schedule), and Reserve Meds concierge fee itemised separately.

Funding and access barriers for Camzyos in Egypt

Obstructive HCM has a population prevalence approximately 1 in 500 and is well-recognised at Egyptian tertiary centres; the historical pharmacological management combines beta-blockers, non-dihydropyridine calcium channel blockers, and disopyramide, with surgical septal myectomy and alcohol septal ablation as procedural alternatives. Camzyos as a first-in-class disease-modifier has no Egyptian-registered equivalent. Public-sector funding: the Universal Health Insurance Authority (UHIA) at uhia.gov.eg is rolling out phased coverage in implementation governorates (Port Said, Ismailia, Suez, Aswan, Luxor, South Sinai, and others as of 2025) with a statutorily broad benefit basket and an HTA process co-developed with UPA; mavacamten has not been adjudicated through the public HTA route. Treatment at State Expense (Nafaqat Ala Al-Dawla, العلاج على نفقة الدولة) is a case-by-case MOHP scheme for Egyptian nationals lacking means; mavacamten adjudication via this route is not a documented precedent. Major private insurers active in Egypt (MetLife Egypt, AXA Egypt, Bupa Egypt through Bupa Arabia, Allianz Egypt, Misr Insurance, Globemed Egypt as TPA, Med Net) typically exclude or sub-limit unregistered named-patient imports in retail policies; corporate group policies with prior authorisation may include with documented step-therapy. Out-of-pocket self-pay dominates as the funding source. The import-permit experience for the oral capsule is procedurally straightforward; the operational complexity sits in the serial-echocardiogram surveillance commitment.

Recent regulatory and access news for Camzyos

FDA expanded the Camzyos indication (June 2025) to non-obstructive HCM in adults based on the ODYSSEY-HCM trial; the approval is summarised at accessdata.fda.gov/scripts/cder/daf. FDA modified the Camzyos REMS (June 2025) reducing the LVEF echocardiogram monitoring burden in stable maintenance patients; the REMS update is at accessdata.fda.gov/scripts/cder/rems. The EDA News feed at edaegypt.gov.eg/en/news does not show a Camzyos-specific bulletin over the last 12 months. UHIA and UPA continue the phased UHI rollout in implementation governorates, each new phase changes the payer mix for unregistered-drug access in that governorate.

Where Reserve Meds fits in Camzyos cases

Reserve Meds is a US-based concierge coordinator. We do not replace your treating physician, we do not replace EDA, and we do not replace your dispensing pharmacy. For Camzyos specifically, we orchestrate the US-side sourcing through a DSCSA-compliant specialty channel, build the documentation packet your physician submits, coordinate validated logistics (cold-chain with continuous temperature logging where the FDA label requires it) into Egypt, and assign a single named coordinator through the case. Standard named-patient coordination under our specialty playbook applies. Presentation selection, dose-band confirmation, and patient onboarding for self-administration where applicable are the recurring operational fundamentals we expect for this drug.

Operationally, a typical Camzyos case runs across four parallel tracks. The clinical track is the physician's: justification letter, dosing plan, monitoring schedule, and the next patient-facing follow-up. The regulatory track is the EDA application packaged by the importer; we provide the documentation template, the dispensing facility license check, and the chain-of-custody attestation. The logistics track is the US-side sourcing and the validated international shipment with continuous temperature logging and customs broker coordination. The patient-experience track is the named coordinator who keeps everyone aligned on dates, addresses dispensing-pharmacy questions, and confirms the medicine has been received and stored correctly. The four tracks are run in parallel rather than in series; that is the operational difference between a 3-week and a 9-week case.

HCM care in Egypt concentrates at Magdy Yacoub Aswan Heart Centre and the National Heart Institute Cairo; EDA Special Access supports mavacamten supply with the FDA REMS echocardiographic monitoring.

Next step

If your Egyptian physician has prescribed Camzyos and you are weighing the cross-border route, the next step is a short intake. We confirm eligibility within 24 to 48 hours and send a documentation kit to your physician.

Start your Camzyos case Or message us on WhatsApp